Introduction: The primary aim of this analysis was to explore whether glycemic control (glycated hemoglobin [HbA1c] \7%) and the incidence of hypoglycemia are different between Chinese patients with type 2 diabetes The online version of this article (results were consistent with the primary analysis results. Conclusions: The results of this analysis provide important real-world information on glycemic control and hypoglycemia in Chinese patients with T2DM, which may be useful for guiding evidenced-based management. Notably, Chinese patients with T2DM receiving OAM-only had poorer glycemic control compared with those receiving insulinonly therapy, although patients receiving OAMonly were less likely to experience hypoglycemic events.
The primary and secondary outcomes were glycemic control and the incidence of hypoglycemia. Primary (multivariate logistic regression analysis with adjustment for potential confounders) and sensitivity analyses (propensity score matching method) were performed.
Results: A higher proportion of patients in the insulin-only group achieved glycemic control than patients in the OAM-only group (41.8% vs 35.9%). Insulin-only treatment was associated with significantly (P = 0.013) better glycemic control than OAM-only treatment ( 
INTRODUCTION
Diabetes is a significant and growing public health issue in China. Indeed, recent estimates suggest that there are over 100 million Chinese adults with diabetes [1] , nearly 500 million with prediabetes [1] , and that there will be more than 140 million Chinese adults with diabetes by 2035 [2] . Worryingly, a high proportion (approximately 60%) of Chinese adults with diabetes remains unaware of their condition and those that are diagnosed tend to have inadequate glycemic control [1] . Specifically, only 41.1% of patients with type 2 diabetes mellitus (T2DM) were found to have glycated hemoglobin (HbA1c) \7.0% (\53 mmol/mol) in the Diabcare China study [3] . In another (crosssectional hospital-based) study, 12.1% to 15.3% of patients were found to have HbA1c \6.5%
(48 mmol/mol) [4] . Unsurprisingly, given that many patients have poor glycemic control, the morbidity and mortality associated with diabetes in China is significant, as indicated by the high proportion (over 50%) of patients who have chronic diabetes-related complications [4] and by the fact that diabetes is one of the major causes of death [5] . Clearly, optimizing treatment strategies will become increasingly important as the population of Chinese patients with diabetes continues to grow.
The current Chinese guidelines for the prevention and treatment of T2DM [6] [3, 7] . Identifying means of improving glycemic control in Chinese patients with T2DM on these regimens is key to preventing diabetes-related complications and morbidities. To date, there is little information in the published literature on differences in glycemic control between Chinese patients with T2DM receiving insulinonly and those receiving OAM-only treatment regimens, or on how patient characteristics affect glycemic control with these regimens.
The information that is available comes from cross-sectional, prospective, or registry studies (carried out in mainland China [7, 8] and Hong Kong [9] ) that did not perform adjustments for potentially confounding patient characteristics.
The availability of appropriately adjusted, realworld data may help facilitate the development of evidence-based treatment strategies for improving glycemic control in Chinese patients with T2DM.
The primary aim of this analysis was to explore whether glycemic control (HbA1c \7%) and the incidence of hypoglycemia are different between Chinese patients with T2DM receiving OAM-only and those receiving insulin-only treatment regimens after adjusting for key patient characteristics. The secondary aim of this analysis was to explore which factors were associated with glycemic control and the incidence of hypoglycemia, respectively. We did not include patients receiving concomitant OAM and insulin treatment regimens in our analyses because regimens for this combination can be highly variable between patients, making it difficult to identify the distinct treatment effects of OAM and insulin individually or separately.
METHODS

Survey Administration
The Adelphi Real World Disease Specific Programme (DSP) is a large, cross-sectional survey of physicians and patients in a realworld clinical setting, which uses representative sampling of treated adult patients for quantification of national disease burden and assessment of treatment patterns and outcomes [10] . The DSP provides a holistic picture of a disease and treatment of that disease; the full methodology of the DSP has been published previously [11, 12] .
The Diabetes DSP was carried out in China from October 2011 to March 2012 in accordance with European Pharmaceutical Marketing Research Association guidelines.
Physicians
were reimbursed for their participation by local fieldwork partners at fair-market rates. DSP fieldwork teams adhered to national data collection regulations.
Survey Distribution
Physicians treating patients with T2DM at general hospitals in Beijing, Shanghai, Guangzhou, Hangzhou, Nanjing, Chengdu, Wuhan, Shenyang, and Xi'an were invited to participate. These physicians were identified by local fieldwork teams from public lists according to predefined selection criteria. Specifically, physicians who had qualified between 1973 and 2009, were actively involved in diabetes management, and saw 25 or more (internal medicine physicians) or 50 or more (diabetologists and endocrinologists) patients with diabetes in a typical week were eligible to participate. Those who agreed to participate were sent physician-report forms [12] for completion. To answer some of the more clinical and indepth questions, the majority of physicians would have had to refer to medical records, in which patients' medical histories, including medication history from different hospitals or physicians would be accurately recorded.
Physician-Report Form
Participating physicians were those most commonly responsible for treating patients with T2DM in China, namely internal medicine physicians, diabetologists, or endocrinologists. Internal medicine physicians were asked to complete physician-report forms for the next nine consecutive patients receiving non-insulin medication with or without insulin regimens and the following two forms for consecutive patients receiving insulin-only regimens. Diabetologists and endocrinologists were asked to complete physician-report forms for the next eight consecutive patients receiving non-insulin medication with or without insulin regimens and the following two forms for consecutive patients receiving insulin-only regimens. The physician-report form quotas per physician for each regimen were based on the prevalence of T2DM in China and the duration of the survey.
Analysis Population
The population for this analysis included patients with T2DM receiving OAM-only or insulin-only treatment regimens for at least 6 months who had most recent HbA1c results available and measured within 3 months of survey completion. Patients were required to be on these regimens for at least 6 months to ensure that the HbA1c result obtained reflected average plasma glucose concentrations during a period of consistent treatment.
Outcomes (OAM-Only vs Insulin-Only)
The primary outcome was glycemic control, defined as HbA1c \7% and determined using the most recent HbA1c test result (assessed at the treating hospital) within 3 months of the survey date.
The secondary outcome was hypoglycemia, defined as any hypoglycemic episode that occurred on the treatment regimen. Hypoglycemic episodes were solicited by physicians from patients and were categorized by incidence as overall, severe, and nocturnal. Patients were provided with practical definitions of hypoglycemia. Mild hypoglycemic episodes were those that were treated by the patient by eating fruit, fruit juice, sweets, etc. Severe hypoglycemic episodes were those where the patient required third party or medical assistance. Hypoglycemia was not confirmed by blood glucose measurement.
As an exploratory, composite outcome, the proportion of patients attaining the HbA1c target \7% without hypoglycemia was also determined.
Statistical Analysis
The patients' characteristics were compared between the OAM-only and insulin-only A two-sided significance level of 0.05 was used for all analyses, which were carried out using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). Adjustments for multiplicity were not made due to the exploratory nature of the analyses.
Compliance with Ethics Guidelines
This article does not contain any new studies with human or animal subjects performed by any of the authors.
RESULTS
Analysis Population
A total of 200 physicians completed 2060 physician-report forms. Of these physicianreport forms, 599 were excluded from the analyses for the following reasons (note: some forms may have had multiple reasons for exclusions):
HbA1c not tested within 3 months, n = 360; received medication for \6 months, n = 262; and time since diagnosis not available, n = 39. Of the remaining 1461 physician-report forms, 1077 were for patients receiving OAM-only regimens, 292 were for patients receiving insulin-only regimens, and 92 were for patients receiving OAM and insulin regimens. The patients receiving OAM and insulin regimens were excluded, leaving 1369 patients on OAM-only or insulin-only regimens for inclusion in the analysis population.
Patient Characteristics
There were several significant differences in patient characteristics between the OAM-only and insulin-only groups (Table 1) . Specifically, patients in the OAM-only group were younger, more recently diagnosed with T2DM, more frequently employed/students, more physically standardized difference \0.1) ( Table 2 ; Fig. 1 ).
Thus, matched patients from the 2 treatment groups were similar and appropriate for use in the sensitivity analysis.
Glycemic Control
Primary Analysis 
Sensitivity Analysis
The results of the sensitivity analysis for hypoglycemia were consistent with the results of the primary analysis. A higher proportion of patients in the insulin-only group reported 
DISCUSSION
This is the first analysis to explore whether glycemic control is different between Chinese patients with T2DM receiving OAM-only and those receiving insulin-only treatment regimens after adjusting for key patient Fig. 1 Standardized differences for patient characteristics before and after propensity score matching. A standardized difference\0.1 was taken to indicate a negligible difference in the mean or prevalence of a covariate between treatment groups [13] . All characteristics were well balanced (standardized difference \0. Importantly, however, we also found that insulin-only treatment regimens may provide better glycemic control than OAM-only treatment regimens in patients with similar core clinical and demographic characteristics.
Previous cross-sectional, prospective, registry, or survey studies carried out in China (mainland [7, 8] and Hong Kong [9] ) and elsewhere [18, 19] comparing glycemic control between patients We found that a number of other factors were associated with glycemic control, including modifiable factors such as patients' dietary adaption, physical activity level, BMI, and treatment compliance, as well as the nonmodifiable factor, duration of disease. These are all well-established factors known to be important in the management of T2DM/ glycemic control [6, 14, [20] [21] [22] [23] . A high level of treatment compliance, more pronounced dietary adaptation, and increased physical activity had the strongest associations with better glycemic control. Our finding regarding treatment compliance is noteworthy given that a high proportion ([80%) of patients were considered to be fairly or fully compliant by their physicians. Therefore, it is clear that [20, 30] .
We also found that self-blood glucose measurement was associated with an increased incidence of hypoglycemia. 
CONCLUSION
In summary, the main finding of our analysis is that insulin-only treatment was associated with better glycemic control than OAM-only treatment in Chinese patients with T2DM. This is an important finding given that glycemic control is essential for preventing diabetes-related complications and that many patients with T2DM in China have inadequate glycemic control. Prospective studies are needed to further explore this finding and determine, considering the increased risk of hypoglycemia, whether certain subsets of Chinese patients with T2DM may benefit from insulin-only treatment rather than OAM-only treatment.
Studies are also needed to determine which potentially modifiable factors targeted for specific interventions may improve outcomes for patients on these regimens.
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